Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Reich

Showing results (181-190 of 218) with videos related to

Pageof 22
Sort By:
Journal of Medical Genetics|December 13, 2005
Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patientsU Hüffmeier, M Steffens, H Burkhardt, et al.
The British Journal of Dermatology|February 19, 2009
Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studiesA Hauschild, E Stockfleth, G Popp, et al.
Genes and Immunity|May 22, 2009
Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case--control studyN Schoof, F von Bonin, I R König, et al.
The British Journal of Dermatology|October 7, 2009
Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months dataR-M Szeimies, E Stockfleth, G Popp, et al.
The British Journal of Dermatology|June 21, 2019
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeksK Reich, R B Warren, L Iversen, et al.
The British Journal of Dermatology|October 10, 2017
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)K A Papp, C L Leonardi, A Blauvelt, et al.
The Journal of Dermatological Treatment|May 1, 2020
Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trialsK B Gordon, K Reich, J J Crowley, et al.
The British Journal of Dermatology|February 9, 2019
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II studyK Reich, P Rich, C Maari, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 1, 2023
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE studyK Schäkel, K Reich, K Asadullah, et al.
The Journal of Dermatological Treatment|November 23, 2020
Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trialsK Reich, A M DeLozier, F P Nunes, et al.
Pageof 22

Showing results (181-190 of 218) with videos related to

Sort By:
Pageof 22
Journal of Medical Genetics|December 13, 2005
Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patientsU Hüffmeier, M Steffens, H Burkhardt, et al.
The British Journal of Dermatology|February 19, 2009
Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studiesA Hauschild, E Stockfleth, G Popp, et al.
Genes and Immunity|May 22, 2009
Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case--control studyN Schoof, F von Bonin, I R König, et al.
The British Journal of Dermatology|October 7, 2009
Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months dataR-M Szeimies, E Stockfleth, G Popp, et al.
The British Journal of Dermatology|June 21, 2019
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeksK Reich, R B Warren, L Iversen, et al.
The British Journal of Dermatology|October 10, 2017
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)K A Papp, C L Leonardi, A Blauvelt, et al.
The Journal of Dermatological Treatment|May 1, 2020
Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trialsK B Gordon, K Reich, J J Crowley, et al.
The British Journal of Dermatology|February 9, 2019
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II studyK Reich, P Rich, C Maari, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 1, 2023
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE studyK Schäkel, K Reich, K Asadullah, et al.
The Journal of Dermatological Treatment|November 23, 2020
Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trialsK Reich, A M DeLozier, F P Nunes, et al.
Pageof 22